Associations - PD-L1-H

PD-L1-H PD-L1-H	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PD-L1-H PD-L1-H	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Resistant: B - Late Trials	trastuzumab Resistant: B - Late Trials
PD-L1-H PD-L1-H	Non-Hodgkin’s Lymphoma NHL	PD-L1-H PD-L1-H	Non-Hodgkin’s Lymphoma NHL	L/P-VIPD Resistant: C3 – Early Trials	L / P-VIPD Resistant: C3 – Early Trials
PD-L1-H PD-L1-H	Urothelial Cancer Urothelial Cancer	PD-L1-H PD-L1-H	Urothelial Cancer Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials	atezolizumab Sensitive: C3 – Early Trials
PD-L1-H PD-L1-H	Non Small Cell Lung Cancer NSCLC	PD-L1-H PD-L1-H	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PD-L1-H PD-L1-H	Bladder Cancer Bladder Cancer	PD-L1-H PD-L1-H	Bladder Cancer Bladder Cancer	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PD-L1-H PD-L1-H	Non Small Cell Lung Cancer NSCLC	PD-L1-H PD-L1-H	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
PD-L1-H PD-L1-H	Neuroendocrine Tumor Neuroendocrine Tumor	PD-L1-H PD-L1-H	Neuroendocrine Tumor Neuroendocrine Tumor	everolimus Resistant: C3 – Early Trials	everolimus Resistant: C3 – Early Trials
PD-L1-H PD-L1-H	Colorectal Cancer CRC	PD-L1-H PD-L1-H	Colorectal Cancer CRC	durvalumab + CP-675206 Resistant: C3 – Early Trials	durvalumab + CP-675206 Resistant: C3 – Early Trials
PD-L1-H PD-L1-H	Solid Tumor Solid Tumor	PD-L1-H PD-L1-H	Solid Tumor Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1-H PD-L1-H	Urothelial Cancer Urothelial Cancer	PD-L1-H PD-L1-H	Urothelial Cancer Urothelial Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1-H PD-L1-H	Small Cell Lung Cancer Small Cell Lung Cancer	PD-L1-H PD-L1-H	Small Cell Lung Cancer Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1-H PD-L1-H	Melanoma Melanoma	PD-L1-H PD-L1-H	Melanoma Melanoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1-H PD-L1-H	Lung Cancer Lung Cancer	PD-L1-H PD-L1-H	Lung Cancer Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials